HER2‐TKIs and anti‐HER2 antibodies have shown limited efficacy in this setting,346, 347 while ADC drug have achieved breakthrough progress in HER2‐mutant NSCLC. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.